Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

Anderson B. Collier; Mark D. Krailo; Ha M. Dang; Steven G. DuBois; Douglas S. Hawkins; Mark L. Bernstein; Lisa R. Bomgaars; Damon R. Reed; Richard G. Gorlick; Katherine A. Janeway

doi:10.1002/pbc.29333

Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

Anderson B. Collier, Mark D. Krailo, Ha M. Dang, Steven G. DuBois, Douglas S. Hawkins, Mark L. Bernstein, Lisa R. Bomgaars, Damon R. Reed, Richard G. Gorlick, Katherine A. Janeway

Pediatrics

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.

Original language	English (US)
Article number	e29333
Journal	Pediatric Blood and Cancer
Volume	68
Issue number	12
DOIs	https://doi.org/10.1002/pbc.29333
State	Published - Dec 2021

Keywords

Ewing sarcoma
event-free survival
objective response
outcome
phase 2 trials
relapsed

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.29333

Cite this

Collier, A. B., Krailo, M. D., Dang, H. M., DuBois, S. G., Hawkins, D. S., Bernstein, M. L., Bomgaars, L. R., Reed, D. R., Gorlick, R. G., & Janeway, K. A. (2021). Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 68(12), Article e29333. https://doi.org/10.1002/pbc.29333

Collier, AB, Krailo, MD, Dang, HM, DuBois, SG, Hawkins, DS, Bernstein, ML, Bomgaars, LR, Reed, DR, Gorlick, RG & Janeway, KA 2021, 'Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group', Pediatric Blood and Cancer, vol. 68, no. 12, e29333. https://doi.org/10.1002/pbc.29333

@article{dd17396a5a6645b1a745edbc3872a552,

title = "Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group",

abstract = "SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.",

keywords = "Ewing sarcoma, event-free survival, objective response, outcome, phase 2 trials, relapsed",

author = "Collier, {Anderson B.} and Krailo, {Mark D.} and Dang, {Ha M.} and DuBois, {Steven G.} and Hawkins, {Douglas S.} and Bernstein, {Mark L.} and Bomgaars, {Lisa R.} and Reed, {Damon R.} and Gorlick, {Richard G.} and Janeway, {Katherine A.}",

note = "Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC",

year = "2021",

month = dec,

doi = "10.1002/pbc.29333",

language = "English (US)",

volume = "68",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "12",

}

TY - JOUR

T1 - Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials

T2 - A report from the Children's Oncology Group

AU - Collier, Anderson B.

AU - Krailo, Mark D.

AU - Dang, Ha M.

AU - DuBois, Steven G.

AU - Hawkins, Douglas S.

AU - Bernstein, Mark L.

AU - Bomgaars, Lisa R.

AU - Reed, Damon R.

AU - Gorlick, Richard G.

AU - Janeway, Katherine A.

PY - 2021/12

Y1 - 2021/12

N2 - SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.

AB - SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.

KW - Ewing sarcoma

KW - event-free survival

KW - objective response

KW - outcome

KW - phase 2 trials

KW - relapsed

UR - http://www.scopus.com/inward/record.url?scp=85114592591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114592591&partnerID=8YFLogxK

U2 - 10.1002/pbc.29333

DO - 10.1002/pbc.29333

M3 - Article

C2 - 34496122

AN - SCOPUS:85114592591

SN - 1545-5009

VL - 68

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 12

M1 - e29333

ER -

Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this